Abeona JPM 2025 Presentation Final 011025.pdf

1、Corporate Presentation January 20252Note regarding forward-looking statementsThis presentation of Abeona Therapeutics Inc.(the“Company”)contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933,as amended,and Section 21E of the Securities Ex

2、change Act of 1934,as amended,and that involve risks and uncertainties.Such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of1995.We have attempted to identify forward-looking statements by such terminology as“may,”“will,”“b

3、elieve,”“anticipate,”“expect,”“intend,”“hope,”and similar expressions(as well as other words or expressions referencing future events,conditions or circumstances),which constitute and are intended to identify forward-looking statements.Actual results may differ materially from those indicated by suc

4、h forward-looking statements as a result of various important factors and numerous risks and uncertainties,including,but not limited to,the timing and outcome of the FDAs review of our resubmitted Biologics License Application for pz-cel,including the FDAs assessment of our responses to the items id

5、entified in the Complete Response Letter relating to pz-cel received from the FDA;potential market opportunities and commercial launch strategies for pz-cel,if approved;the FDAs grant of a Priority Review Voucher upon a potential approval of pz-cel;continued interest in our rare disease portfolio;th

6、e timing of studies or study manuscript submissions;our ability to enroll patients in clinical trials;the outcome of future meetings with the FDA or other regulatory agencies,including those relating to our preclinical programs;our ability to achieve or obtain necessary regulatory approvals;the impa